These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 22449781)

  • 21. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
    Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
    Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
    Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity.
    Backlund CM; Holden RL; Moynihan KD; Garafola D; Farquhar C; Mehta NK; Maiorino L; Pham S; Iorgulescu JB; Reardon DA; Wu CJ; Pentelute BL; Irvine DJ
    Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2204078119. PubMed ID: 35914154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immunological effects of mRNA vaccines in malignant diseases.
    Heine A; Juranek S; Brossart P
    Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?
    Liu Q; Wu P; Lei J; Bai P; Zhong P; Yang M; Wei P
    Int J Biol Macromol; 2024 Nov; 279(Pt 4):135541. PubMed ID: 39270889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Next-generation peptide vaccines for advanced cancer.
    Yamada A; Sasada T; Noguchi M; Itoh K
    Cancer Sci; 2013 Jan; 104(1):15-21. PubMed ID: 23107418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Tumor Antigens and Cancer Immunotherapy.
    Vigneron N
    Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
    Wang RF
    Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Journey of
    Goyvaerts C; Breckpot K
    Front Immunol; 2018; 9():2052. PubMed ID: 30254636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing dendritic cell-based approaches for cancer immunotherapy.
    Datta J; Terhune JH; Lowenfeld L; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Yale J Biol Med; 2014 Dec; 87(4):491-518. PubMed ID: 25506283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In Vivo Antigen Delivery to Dendritic Cells-A Novel Peptide Vaccine for Cancer Therapy].
    Mizumoto Y; Katsuda M; Miyazawa M; Kitahata Y; Miyamoto A; Nakamori M; Ojima T; Matsuda K; Hemmi H; Tamada K; Kaisho T; Yamaue H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1469-1471. PubMed ID: 30382048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.